Promising Results in EGFR-Mutated Lung Cancer with Iza-bren and Osimertinib Combination Therapy
A new study demonstrates that combining iza-bren with osimertinib yields a 100% response rate in patients with EGFR-mutated non-small cell lung cancer, offering hope for improved first-line treatment options.
A recent clinical study has revealed highly encouraging outcomes for patients with first-line EGFR-mutated non-small cell lung cancer (NSCLC) treated with a novel combination of iza-bren and osimertinib. Iza-bren, a groundbreaking bispecific antibody-drug conjugate (ADC) that targets EGFR and HER3 while delivering a topoisomerase I inhibitor payload, was paired with daily osimertinib, a third-generation EGFR tyrosine kinase inhibitor.
Presented at the 2025 World Conference on Lung Cancer, the study involved 154 patients across multiple dose levels. In particular, the group receiving 2.5 mg/kg of iza-bren achieved a 100% objective response rate (ORR), with a confirmed ORR of 95%, indicating that nearly all patients experienced tumor shrinkage. The median follow-up period was 12.8 months, with a 92.1% progression-free survival (PFS) rate at 12 months. Notably, the median duration of response and PFS had not yet been reached at the time of analysis.
The safety profile was manageable, with most treatment-related adverse events being hematologic, such as anemia (91.9%), neutropenia (91.1%), leukopenia (91.1%), and thrombocytopenia (75.6%). Non-hematologic side effects included nausea, stomatitis, decreased appetite, vomiting, diarrhea, and rash. Grade 3 or higher adverse events were controllable through supportive care and dose adjustments, with a discontinuation rate of 13%.
Dr. Fei Zhou, the lead investigator, expressed optimism about the findings, highlighting the potential for this combination to become a transformative first-line therapy for EGFR-mutant NSCLC. The promising activity and manageable safety profile suggest that future studies could solidify its place in lung cancer treatment options.
This groundbreaking research underscores ongoing advancements in targeted therapies for lung cancer, aiming to improve outcomes for patients with EGFR mutations.
For more details, visit the original report at Medical Xpress.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Brain Imaging System Uses Upright PET and AR Eye Tracking to Enhance Cognitive Disorder Research
A new brain imaging platform combining upright PET with AR eye tracking is revolutionizing cognitive disorder research by providing more naturalistic insights into brain activity. This innovative system enhances early detection of neurodegenerative diseases like Alzheimer's and Parkinson's.
Increased Risk of Intraocular Inflammation with Aflibercept Injections in Real-World Practice
Real-world use of aflibercept injections shows a higher incidence of mild intraocular inflammation compared to clinical trials, emphasizing the need for careful patient monitoring and education.
Hidden Body Fat Accelerates Heart Aging Through Visceral Fat
New research links hidden visceral fat to accelerated heart aging, highlighting the importance of fat distribution in cardiovascular health and potential hormone influences.
Could Caffeine Play a Role in Preventing Sudden Infant Death Syndrome?
Research suggests caffeine might help prevent Sudden Infant Death Syndrome by counteracting low oxygen episodes in infants. This innovative hypothesis could open new pathways for prevention strategies in infant health.